Since 2014, the Drug Enforcement Administration (DEA) Philadelphia Division Intelligence Program (PDIP) has annually collected and analyzed data and disseminated perceived trends and key findings that concern drug-related overdose deaths in Pennsylvania. This analysis has informed a multi-disciplinary audience relating to the drugs, populations, and geographic areas of greatest concern...

Statement of Matthew Donahue before the House of Representatives, Energy and Commerce Committee, Subcommittee on Oversight and Investigations for a hearing entitled, Oversight of Federal Efforts to Combat the Spread of Illicit Fentanyl.

Greg Cherundolo Chief of Operations Office of Global Enforcement Drug Enforcement Administration U.S. Department of Justice before the United States Senate Judiciary Committee for hearing entitled: The Countdown: Fentanyl Analogues and the Expiring Emergency Scheduling Order.

The Drug Enforcement Administration (DEA) Philadelphia Division’s Intelligence Program (PDIP) reviewed a set of data indicators for the years 2015-2018 to assess the current prescription opioid threat in Pennsylvania. Analysis revealed that a positive change in the prescription opioid threat may be underway...

Greg Cherundolo Chief of Operations Office of Global Enforcement Drug Enforcement Administration U.S. Department of Justice before the United States Senate Homeland Security and Governmental Affairs Committee

Acting Administrator Uttam Dhillon at the Drugs: Cost and Consequences Press Conference, Museum of Natural History and Science, Albuquerque, New Mexico

What is prescription pain reliever misuse? As defined by the National Survey on Drug Use and Health, it’s “use without a prescription of one’s own or use at a higher dosage or more often than prescribed.” Prescription opioid addiction – stemming from misuse – has hit the nation hard in...

Acting Administrator Uttam Dhillon at the University of South Carolina-Aiken, Chancellor’s Signature Speaker Series Aiken, South Carolina

Statement of Paul E. Knierim Deputy Chief of Operations, Office of Global Enforcement Drug Enforcement Administration Before the Subcommittee on Border Security and Immigration Committee on the Judiciary United States Senate

The DEA Heroin Domestic Monitor Program (HDMP) is a retail-level heroin purchase program that provides data analysis about the geographic source of heroin along with price, purity, adulterants, and diluents sold at the street-level in 27 U.S. cities. The data in this report is from 2016.